TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio (NASDAQ: TELA) announced inducement restricted stock unit grants to three newly hired employees totaling 3,600 shares, with a grant date of December 9, 2025.
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) announced inducement restricted stock unit grants to three newly hired employees totaling 3,600 shares, with a grant date of December 9, 2025. The Compensation Committee approved the awards under the Nasdaq Rule 5635(c)(4) inducement exception as part of each hire's employment compensation.
The restricted stock units vest in equal annual installments over four years, subject to each employee's continued service through applicable vesting dates.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TELA
On Dec 15, the first trading day after this news, TELA closed 1.74% below the previous close.
Data tracked by StockTitan Argus for the Dec 15 session.
Key Figures
- RSU shares granted
- 3,600 shares
- Inducement RSUs to three new employees, Grant Date Dec 9, 2025
- Employees receiving grants
- 3 employees
- New hires receiving RSU inducement awards
- Vesting period
- 4 years
- RSUs vest in equal annual installments over four years
Historical Context
-
Announcement of presentation at Piper Sandler healthcare investor conference.
-
Inducement RSUs and stock option grants for new employees under Nasdaq rules.
-
Pricing of $13.0M registered direct offering of common stock and pre-funded warrants.
-
Q3 2025 growth, narrowed losses, and new $70M credit facility announcement.
-
Scheduling notice for upcoming Q3 2025 earnings release and conference call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
Nasdaq Rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Dec. 12, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 3,600 shares of its common stock to three newly-hired employees, with a grant date of December 9, 2025 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.